Daily Roundup

Kingston Resources Strikes Gold with Jack's Hut Results

Kingston Resources is building momentum at its Mineral Hill project with excellent infill drilling results from the Jack's Hut deposit. The company is zeroing in on making Jack's Hut its second underground ore source, and the latest drilling has confirmed what geologists were hoping to find—solid mineralisation that matches the existing geological model. The results give the team real confidence about the location, continuity, and grade of ore around the conceptual stope areas. Coming up in October, surface drilling will push deeper to test whether the deposit extends further down dip. All of this feeds into an updated Mineral Resource estimate that Kingston is targeting for the March quarter of 2027.

Krakatoa Resources Uncovers High-Grade Gold and Antimony in Georgia

Over in Georgia, Krakatoa Resources is reporting impressive assay results from its Zopkhito Antimony-Gold Project. The first batch of results from this year's drilling program reveals multiple zones of significant mineralisation, with peak grades hitting 17.1g/t gold and 15.3% antimony. The standout result came in at 1.8 metres grading 11.09g/t gold and 3.56% antimony. What's particularly encouraging is that the results confirm the continuity of mineralisation and align perfectly with both last year's findings and historical high-grade data. The company's 2026 exploration program is focused on converting the existing foreign resource estimate into a proper JORC 2012 standard Mineral Resource Estimate, with surface and underground drilling continuing to expand the footprint of the mineralised veins.

Black Cat Syndicate Brings in Experienced Leadership

Black Cat Syndicate has appointed Chris Stone as Acting Managing Director, effective 8 September. Stone brings over 35 years of mining industry experience across gold, nickel, copper, and coal operations. He'll be steering the company through the transition period while the board searches for a permanent replacement. His track record includes leadership roles at major mining operations with a strong emphasis on safety, technical functions, and stakeholder engagement.

Echo IQ Hits a Regulatory Roadblock with EchoSolv HF

Echo IQ has received disappointing news from the FDA regarding its EchoSolv HF device. The company's initial 510(k) application came back with a Not Substantially Equivalent determination, meaning it won't be cleared for commercial use in its current form. The company is now working with its US regulatory and legal advisors to understand the FDA's concerns and explore alternative pathways forward. Despite the setback, Echo IQ remains confident in the clinical rationale for the technology and the significant unmet need in heart failure identification. On the brighter side, the company's EchoSolv AS product continues to gain traction in the US market, and it's sitting in a strong financial position with over $105 million in cash. The broader R&D pipeline also remains robust.

BTC Health Faces Supply Chain Disruption

BTC Health is navigating a significant challenge after Arna Pharma, the manufacturer of Bronchitol® and Aridol®, entered voluntary administration on 7 September. While BTC Health itself isn't financially exposed to Arna Pharma, the disruption will impact sales. BTC Pharma, the wholly-owned subsidiary that holds exclusive Australian distribution rights, currently has about eight months of Bronchitol® stock on hand but less than a month of Aridol® inventory. The company is projecting that sales of these products will drop to around $0.5 million in FY2027 without further supply. BTC Pharma is actively engaging with the administrators and relevant authorities to work out continuity of supply, though Arna Pharma has indicated its intention to recapitalize and maintain operations.